miR-146a Attenuates Sepsis-Induced Myocardial Dysfunction by Suppressing IRAK1 and TRAF6 via Targeting ErbB4...

Area of Science:

• Cardiovascular Biology
• Molecular Biology
• Immunology

Background:

• Sepsis-induced myocardial dysfunction is a critical factor in mortality.
• MicroRNA-146a (miR-146a) is a key negative regulator of innate immune and inflammatory responses.
• Lipopolysaccharide (LPS) is a common inducer of sepsis and inflammation.

Purpose of the Study:

• To investigate the role of miR-146a in sepsis-induced cardiac dysfunction.
• To elucidate the regulatory mechanism of miR-146a involving ErbB4 signaling.

Main Methods:

• H9C2 cells were treated with LPS to simulate sepsis.
• miR-146a was overexpressed to assess its effects.
• Cell viability, apoptosis, reactive oxygen species (ROS), and cytokine release were measured.
• Protein levels of ErbB4, NF-κB pathway components, apoptosis markers, and Bcl-2/Bax ratio were analyzed via Western blot.
• siErbB4 was used to confirm the role of ErbB4.

Main Results:

• Overexpression of miR-146a enhanced cell viability, reduced apoptosis and ROS levels, and decreased pro-inflammatory cytokines (TNF-α, IL-1β).
• miR-146a increased ErbB4 expression while decreasing TRAF6, IRAK1, caspase 3, and p-NF-κB levels.
• miR-146a increased the Bcl-2/Bax ratio, indicating reduced apoptosis.
• The protective effects of miR-146a were dependent on ErbB4, as confirmed by siErbB4 treatment.

Conclusions:

• miR-146a overexpression mitigates myocardial injury in LPS-induced sepsis.
• This protection is achieved by negatively regulating NF-κB activation and inflammatory cytokine production.
• The mechanism involves targeting ErbB4 signaling, highlighting a novel therapeutic pathway.